In 2018, OHSU OPAT/Infectious Diseases and IMPACT (addiction medicine) partnered to develop the OPTIONS-DC multidisciplinary discharge planning conference for those with SUD requiring long term IV antibiotics.  The conference uses frameworks of harm reduction and patient centered care to create discharge options acceptable to both providers and patients.  We strive to continue to learn, share, and implement harm reduction practices while approaching treatment discussions for persons who use drugs (PWUD). 

Honors

• CORMAN IMPACT Award
• OHSU Equity and Inclusion Grant Award 2021 and 2022

OHSU OPAT published work specific to treatment of PWUD

• Conte M, Schneider B, Varley C, Streifel AC, Sikka MK. Description and Outcomes of Patients with Substance Use Disorder with Serious Bacterial Infections who has a Multidisciplinary Care Conference. Therapeutic Advances in Infectious Diseases. 2022; 9:20499361221117974. doi: 10.1177/20499361221117974
• Sikka MK, Gore S, Vega T, Strnad L, Gregg J, Englander H. “OPTIONS-DC”, a feasible discharge planning conference to expand infection treatment options for people with substance use disorder. BMC Infectious Diseases. 2021; 21:772. doi: 10.1186/s12879-021-06514-9.
• Hurley H, Sikka M, Jenkins T, Cari EV, Thornton A. Outpatient Antimicrobial Treatment for People Who Inject Drugs. Infect Dis Clin North Am. 2020;34(3):525-538. doi: 10.1016/j.idc.2020.06.009

Selected Abstracts

• Douglass A, Mayer H, Young K, Streifel AC, Franklin H, Strnad L, Makadia J, Sikka M. A Review of Antibiotic Outcomes Data Utilizing the Multidisciplinary OPTIONS-DC Conference for PWUD. (Accepted for poster presentation at IDweek 10/22/2022, Washington D.C, USA)
• Young K, Mayer H, Douglass A, OPTIONS-DC: A new standard in serious infection discharge planning for those with Substance Use Disorders. (Accepted for poster presentation at IntNSA 10/27/2022, Calgary, CA)
• Douglass A, Mayer H, Young K, Streifel AC, Makadia J, Lewis J, Sikka MK. 625. The Hidden Cost of Dalbavancin: OPAT-RN Time Spent on Coordination for Patients with Substance Use Disorder. Open Forum Infect Dis. 2021;8(Suppl 1):S416–7. doi: 10.1093/ofid/ofab466.823
• Streifel AC, Makadia J, Luke S, Douglass A, Mayer H, Young K, Lewis J, Sukerman E, Sikka M. 122. Dalbavancin Use in Patients with Substance Use Disorders. Open Forum Infect Dis. 2020 Dec;7(Suppl 1):S189–90. doi: 10.1093/ofid/ofaa439.432

Past Presentations

• A Review of Antibiotic Outcomes Data Utilizing the Multidisciplinary OPTIONS-DC Conference for PWUD 10/2023
  •  IDweek rapid fire presentation
• OPTIONS-DC early outcomes 6/2022
  • Audience:  Portland area Infectious Diseases Citywide
• PICCKles: Central Line Complications in OPAT 8/2021
  • Audience:  Portland area Infectious Diseases Citywide
• Treating Infections in Patients with Substance Use Disorder 10/2019
  • Audience: Infusion Nurse's Society Oregon Chapter Fall Conference
• Management of Long-Term Intravenous Antibiotics and PICC Lines 2/2019
  • Audience: Substance Use Disorders in Hospital Care ECHO  
• OPTIONS-DC: A New Approach to Complex Treatment Planning for People Who Use Drugs with Serious Infections 3/16/2023
  • Audience: the Department of Infectious Diseases at The Alfred Hospital and Monash University in Melbourne, Australia.